| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/24/2003 | US20030078411 Adeno-associated virus capsid immunologic determinants |
| 04/24/2003 | US20030078409 Nucleotide sequences coding polypeptide for use in the treatment of respiratory system, asthmatic and inflammatory bowel diseases |
| 04/24/2003 | US20030078405 47 human secreted proteins |
| 04/24/2003 | US20030078391 Nucleotide sequences coding polypeptide for use in treatment of periodontal disease |
| 04/24/2003 | US20030078389 Gamma-heregulin |
| 04/24/2003 | US20030078386 Antibody for use in the treatment of viral, gastrointestinal, autoimmune and cell proiferative disorders |
| 04/24/2003 | US20030078376 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 04/24/2003 | US20030078304 Administering to animal or man of at least one type of xanthophyll in an amount inhibiting the expression of inflammatory cytokines and chemokines in animal or man |
| 04/24/2003 | US20030078300 Fused bicyclic or tricyclic amino acids |
| 04/24/2003 | US20030078299 Anti-cancer nitro- and thia-fatty acids |
| 04/24/2003 | US20030078286 For therapy of central nervous system disorders such as anxiety, depression, motor disorders |
| 04/24/2003 | US20030078284 Materials and methods for the treatment of depression |
| 04/24/2003 | US20030078281 Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
| 04/24/2003 | US20030078280 Macroheterocylic compounds useful as kinase inhibitors |
| 04/24/2003 | US20030078279 For therapy and prophylaxis of pain, central nervous system disorder or the like in mammalian subjects |
| 04/24/2003 | US20030078278 Spiropiperidine compounds as ligands for ORL-1 receptor |
| 04/24/2003 | US20030078276 Matrix metalloproteinase inhibitors |
| 04/24/2003 | US20030078275 For therapy of cancer, diabetes and Alzheimer's disease |
| 04/24/2003 | US20030078274 Method of reducing neuronal injury or apoptosis |
| 04/24/2003 | US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| 04/24/2003 | US20030078265 Inhibitors of nitric oxide synthase (nos) |
| 04/24/2003 | US20030078261 Prostaglandin agonists |
| 04/24/2003 | US20030078259 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders |
| 04/24/2003 | US20030078258 Adrenergic blocking agents |
| 04/24/2003 | US20030078257 Methods of treating tumors |
| 04/24/2003 | US20030078254 Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 04/24/2003 | US20030078252 Used to treat abnormal cell growth and central nervous system disorders |
| 04/24/2003 | US20030078246 Combinations for the treatment of inflammatory disorders |
| 04/24/2003 | US20030078241 Treating effects of excessive reactive oxygen species |
| 04/24/2003 | US20030078239 Ketone compounds and compositions for cholesterol management and related uses |
| 04/24/2003 | US20030078236 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
| 04/24/2003 | US20030078234 Applying semi-crystalline acetylglucosamine polysaccharide for treating vasoconstriction, reduction in blood flow |
| 04/24/2003 | US20030078232 A stimulants for bone marrow cell proliferation, countering the toxic side effect of drugs, in particular chemotherapeutic drugs, such as leukopenia and neutropenia |
| 04/24/2003 | US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 04/24/2003 | US20030078200 Treating a DSM-III disorder by administering to a mammal a peptide or a peptidomimetic thereof to reduce or eliminate symptoms of the DSM-III disorder |
| 04/24/2003 | US20030078193 Therapeutic Agents For Diabetes |
| 04/24/2003 | US20030078189 Medicinal compositions for oral use |
| 04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077798 Nucleotide sequences coding polypeptide for use in the treatment of alzheimer's, diabetes and inflammation |
| 04/24/2003 | US20030077750 Peptide for use in human therapeutics and diagnostics |
| 04/24/2003 | US20030077749 Ucp5 |
| 04/24/2003 | US20030077735 Novel human Kchannel and therapeutic applications thereof |
| 04/24/2003 | US20030077706 Mouse cytokine receptor |
| 04/24/2003 | US20030077705 Nucleotide sequences coding polypeptide for use in the treatment of inflammation and ischemia-reperfusion injury |
| 04/24/2003 | US20030077694 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory disorders |
| 04/24/2003 | US20030077683 IKK-alpha proteins, nucleic acids and methods |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077628 Detection of preferential binding particles; obtain ligand sample, incubate with liquid crystal solution, expose to spectrum analysis, compare to control, monitor binding activity |
| 04/24/2003 | US20030077565 Preservation of corneal graft in vitro; obtain graft, incubate with antisense oligonucleotides in solution, monitor viability of graft tissue |
| 04/24/2003 | US20030077341 Processes of making North American ginseng fractions, products containing them, and use as immunomodulators |
| 04/24/2003 | US20030077340 Lipid is coconut oil esterified with fatty acid |
| 04/24/2003 | US20030077339 Plant extract for diabetic therapy |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077279 Methods for treating vascular disease by inhibiting toll-like receptor-4 |
| 04/24/2003 | US20030077277 Human antibodies that have MN binding and cell adhesion-neutralizing activity |
| 04/24/2003 | US20030077258 Comprising one or more chondroitin sulfate proteoglycan (CSPG)-degrading enzymes that promote axonal penetration into damaged nerve tissue and nerve graft |
| 04/24/2003 | US20030077252 Vaccination against plaque forming diseases; inhibiting aggregation of amyloid in mammal and/or to cause disaggregation of amyloid; treating brain disorder, Alzheimer's disease |
| 04/24/2003 | US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer |
| 04/24/2003 | US20030077247 Chemokines as adjuvants of immune response |
| 04/24/2003 | US20030077243 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/24/2003 | CA2684419A1 Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity |
| 04/24/2003 | CA2463996A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | CA2463943A1 Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 04/24/2003 | CA2463908A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | CA2463850A1 Remodeling of tissues and organs |
| 04/24/2003 | CA2463816A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 04/24/2003 | CA2463754A1 Concomitant oral and topical administration of anti - infective agents |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463724A1 Organosulfur inhibitors of tyrosine phosphatases |
| 04/24/2003 | CA2463686A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 04/24/2003 | CA2463685A1 Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 04/24/2003 | CA2463682A1 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | CA2463628A1 Himbacine analogues as thrombin receptor antagonists |
| 04/24/2003 | CA2463571A1 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| 04/24/2003 | CA2463518A1 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | CA2463509A1 Lactam derivatives as antagonists for human 11cby receptors |
| 04/24/2003 | CA2463508A1 Pyrimidinones as melanin concentrating hormone receptor 1 |
| 04/24/2003 | CA2463469A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | CA2463435A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 04/24/2003 | CA2463426A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 04/24/2003 | CA2463425A1 Titanium-group metal containing high-performance water, and its producing method and apparatus |
| 04/24/2003 | CA2463395A1 Therapeutic agents for low hdl-cholesterolemia |
| 04/24/2003 | CA2463159A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
| 04/24/2003 | CA2463017A1 Method for preparation of single chain antibodies |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2462713A1 Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone |
| 04/24/2003 | CA2462514A1 Dicarboxylic acid derivatives, their preparation and therapeutical use |
| 04/24/2003 | CA2462442A1 Alkyne matrix metalloproteinase inhibitors |
| 04/24/2003 | CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | CA2461550A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2458981A1 Combinations comprising cox-2 inhibitors and aspirin |
| 04/24/2003 | CA2454578A1 Modified human thymic stromal lymphopoietin |
| 04/23/2003 | EP1304379A2 Humanised antibody against CD18 |
| 04/23/2003 | EP1304378A1 ARL-2 for fertility control |
| 04/23/2003 | EP1304327A2 Glutamine-thiazolidide and -pyrrolidide and their use as dipeptidylpeptidase IV inhibitors |
| 04/23/2003 | EP1304324A1 Serotonin reuptake inhibitors |